How BCG led to the discovery of immunostimulatory DNA

Japanese Journal of Infectious Diseases

Volumn 52, Issue 1, 1999, Pages 1-11

  Tokunaga, Tohru ^a   Yamamoto, Toshiko ^b   Yamamoto, Saburo ^b  

^a Fukuoka Jo Gakuin University   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BACTERIAL DNA; BCG VACCINE; CYTOKINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; PLASMID VECTOR; VACCINE;

ALLERGY; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CANCER INHIBITION; DNA PURIFICATION; GENE THERAPY; HOST RESISTANCE; HUMAN; INFECTION; INJECTION PAIN; INVERTEBRATE; MYCOBACTERIUM BOVIS; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; PLANT; REVIEW; SKIN CANCER; SPLEEN CELL; TUMOR RESISTANCE; VERTEBRATE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BASE SEQUENCE; DNA, BACTERIAL; DNA, VIRAL; HUMANS; INVERTEBRATES; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM BOVIS; NEOPLASMS;

EID: 0032829670     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Chase, M. W. (1945): The cellular transfer of cutaneous hypersensitivity to tuberculin. Proc. Soc. Exp. Biol. Med., 59, 134-135.
2. Freund, J., Thomson, K. T., Hough, H. B., Sommer, H. E. and Pisani, T. M. (1948): Antibody formation and sensitization with the aid of adjuvants. J. Immunol., 60, 383-398.
3. Mackaness, G. B. (1964): The immunological basis of acquired cellular resistance. J. Exp. Med., 120, 105-120.
4. Shevach, E. M., Rosenthal, A. S. (1973): Function of macrophages in antigen recognition by guinea pig T lymphocytes. II. Role of the macrophage in the regulation of genetic control of the immune response. J. Exp. Med., 138, 1213-1229.
5. Herberman, R. B., Nunn, M. E. and Lavrin, D. H. (1975): Natural cytotoxic reactivity mediated by murine splenocytes. p.201-208. In Herberman, R. B. (ed.), NK cells and other natural effector cells. Academic Press, N.Y.
6. Bloom, B. R. and Bennett, B. (1966): Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science, 153, 80-82.
7. David, J. R. (1966): Delayed hypersensitivity in vitro: Its mediation by cell-free substaneous formed by lymphoid cell antigen interaction. Proc. Natl. Acad. Sci., USA, 56, 72-77.
8. Bast, R. C., Zbar, B., Borsos, T. and Rapp, H. J. (1974): BCG and cancer. New Engl. J. Med., 290, 1413-1458.
9. Tokunaga, T., Yamamoto, H., Shimada, S., Abe, H., Fukuda, T., Fujisawa, Y., Furutani, Y., Yano, O., Kataoka, T., Sudo, T., Makiguchi, N. and Suganuma, T. (1984): Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst., 72, 955-962.
10. Shimada, S., Yano, O. and Tokunaga, T. (1986): In vivo augmentation of natural killer cell activity with a deoxyribo-nucleic acid fraction of BCG. Jpn. J. Cancer Res (Gann), 77, 808-816.
11. Yamamoto, S., Kuramoto, E., Shimada, S. and Tokunaga, T. (1988): In vitro augmentation of natural killer cell activity and production of interferon- α/β and -γ with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn. J. Cancer Res (Gann), 79, 866-873.
12. Tokunaga, T., Yano, O., Kuramoto, E., Kimura, Y., Yamamoto, T., Kataoka, T. and Yamamoto, S. (1992): Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol. Immunol., 36, 55-66.
13. Kuramoto, E., Yano, O., Kimura, Y., Baba, M., Makino, T., Yamamoto, S., Yamamoto, T., Kataoka, T. and Tokunaga, T. (1992): Oligonucleotide sequences required for natural killer cell activation. Jpn. J. Cancer Res., 83, 1128-1131.
14. Yamamoto, S., Yamamoto, T., Shimada, S., Kuramoto, E., Yano, E., Yano, O., Kataoka, T. and Tokunaga, T. (1992): DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol. Immunol., 36, 983-997.
15. Stein, C. A. (1995): Does antisense exist ? It may, but only under very special circumstances. Nature Medicine, 1, 1119-1121.
16. Pisetsky, D. S. (1996): Immune activation by bacterial DNA: A new genetic code. Immunity, 5, 303-310.
17. Krieg, A. M. (1996): An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J. Lab. Clin. Med., 128, 128-133.
18. Krieg, A. M., Yi, A-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A. and Klinman, D. M. (1995): CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 374, 546-549.
19. Raffel, S., Arnaud, Le., Dukes, D. and Huang J. S. (1949): Role of the "wax" of the tubercle bacillus in establishing delayed hypersensitivity II. Hypersensitivity to a protein antigen, egg albumin. J. Exp. Med., 90, 53-72.
20. 3. J. Natl. Cancer Inst., 52, 95-101.
21. Weiss, D. W., Bonhag, R. S. and Parks, J. A. (1964): Studies on the heterologous immunogenicity of a methanol-insoluble fraction of attenuated tubercle bacilli (BCG). J. Exp. Med., 119, 53-70.
22. Hiu, I. J. (1972): Water-soluble and lipid-free fracton from BCG with adjuvant and antitumor activity. Nature (New Biol), 238, 241-242.
23. Minden, P., McClatchy, J. K., Wainberg, M. and Weiss, D. W. (1974): Shared antigens between Mycobacterium bovis (BCG) and neoplastic cells. J. Natl. Cancer Inst., 53, 1325-1331.
24. Sato, H., Yokosawa, A., Arai, H., Nagai, H., Kurita, K., Kumano, N., Motomiya, M. and Konno, K. (1976): Chemical and biological properties of hot-water extract from delipidated cells of Mycobacterium bovis Strain BCG. Tohoku J. Exp. Med., 120, 75-81.
25. Adam, A., Ciobaru, R., Petit, J-F. and Lederer, E. (1972): Isolation and properties of a macromolecular, water-soluble, immunoadjuvant fraction from the cell wall of Mycobacterium smegmatis. Proc. Natl. Acad. Sci. USA., 69, 851-854.
26. Shimada, S., Yano, O., Inoue, H., Kuramoto, E., Fukuda, T., Yamamoto, H., Kataoka, T. and Tokunaga, T. (1985): Antitumor activity of the DNA fraction from Mycobacterium bovis BCG. II. Effects on various syngeneic mouse tumors. J. Natl. Cancer Inst., 74, 681-688.
27. Tokunaga, T., Yamamoto, S. and Namba, K. (1988): A synthetic single-stranded DNA, poly (dG,dC), induces interferon-α/β and -γ, augments natural killer activity, and suppresses tumor growth. Jpn. J. Cancer Res. (Gann), 79, 682-686.
28. Kuramoto, E., Toizumi, S., Shimada, S., and Tokunaga, T. (1989): In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. Microbiol. Immunol., 33, 929-940.
29. Kuramoto, E., Watanabe, N., Iwata, D., Yano, O., Shimada, S. and Tokunaga, T. (1992): Changes of host cell infiltration into meth A fibrosarcoma tumor during the course of regression induced by infections of a BCG nucleic acid fraction. Int. J. Immunopharmac., 14, 773-782.
30. Mashiba, H., Matunaga, K., Tomoda, H., Furusawa, M., Jimi, S. and Tokunaga, T. (1988): In vitro augmentation of natural killer activity of peripheral blood cells from cancer patients by a DNA fraction from Mycobacterium bovis BCG. Japan. J. Med Sci. Biol., 41, 197-202.
31. Kataoka, T., Yamamoto, S., Yamamoto, T., Kuramoto, E., Kimura, Y. and Tokunaga, T. (1992): Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG. Jpn. J. Cancer Res., 83, 244-247.
32. Yamamoto, S., Yamamoto, T., Kataoka, T., Kuramoto, E., Yano, O. and Tokunaga, T. (1992): Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J. Immunol., 148, 4072-4076.
33. Yamamoto, T., Yamamoto, S., Kataoka, T., Komuro, K., Kohase, M. and Tokunaga, T. (1994): Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. Jpn. J. Cancer Res., 85, 775-779.
34. Ballas, Z. K., Rasmussen, W. L. and Krieg, A. M. (1996): Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol., 157, 1840-1845.
35. Yamamoto, T., Yamamoto, S., Kataoka, T. and Tokunaga, T. (1994): Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res. Develop, 4, 119-122.
36. Kimura, Y., Sonehara, K., Kuramoto, E., Makino, T., Yamamoto, S., Yamamoto, T., Kataoka, T. and Tokunaga, T. (1994): Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. J. Biochem., 116, 991-994.
37. Yamamoto, T., Yamamoto, S., Kataoka, T. and Tokunaga, T. (1994): Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. Microbiol. Immunol., 38, 831-836.
38. Sonehara, K., Saito, H., Kuramoto, E., Yamamoto, S., Yamamoto, T. and Tokunaga, T. (1996): Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. J. Interferon Cytokine Res., 16, 799-803.
39. Bird, A. P. (1986): CpG-rich islands and the function of DNA methylation. Nature, 321, 209-213.
40. Special issue (1990): Basic studies of MY-1, a new biological response modifier, Jpn. Pharmacology & Therapeutics, 18, Suppl., 6 1-347 (in Japanese).
41. Majima, H. and Nomura, K. (1986): Phase 1 clinical study of MY-1, A new biological response modifier. Jpn. J. Cancer Chemother. 13, 109-115 (in Japanese).
42. Ochiai, T., Suzuki, T., Nakajima, K., Asano, T., Mukai, M., Kouzu, T., Okayama, K., Isono, K., Nishijima, H. and Ohkawa, M. (1986): Studies on lymphocyte subsets of regional lymphodes after endoscopic injection of biological response modifiers in gastric cancer patients. Int. J. Immunotherapy II, 4, 259-265.
43. Ishihara, K., Ikeda, S., Arao, T. and Matsunaka, M. (1988): Pilot study on local administration of a new BRM, MY-1, For the treatment of malignant skin tumors, Skin Cancer, 3, 273-281 (in Japanese).
44. Ishihara, K., Ikeda, S. and Furue, H. (1990): Late Phase-II clinical study of MY-1 in the treatment of malignant skin tumors, Skin Cancer, 5, 192-202 (in Japanese).
45. Johno, M., Arao, T. and Ishihara, K. (1991): Adult T-cell leukemia/lymphoma and mycosis fungoides responding well to MY-1. West Jpn. Dermatol., 53, 1297-1306 (in Japanese).
46. Boggs, R. L., McGraw, K., Condon, T., Flournoy, S., Villiet, P., Bennett, C. F. and Monia, B. P. (1997): Characterization and modulation of immune stimulation by modified oligonucleotides. Antisese Nucleic Acid Drug Develop., 7, 461-471.
47. Monteith, D. K., Henry, S. P., Howard, R. B., Flournoy, S., Levin, A.A., Bennett, C. F. and Crooke, S. T. (1997): Immune stimulation - a class effect of phosphorothioate oliginucleotides in rodents. Anti-Cancer Drug Design, 12, 421-432.
48. Klinman, D. M., Yi, A-K., Beaucaga, S. L., Conover, J. and Krieg, A. M. (1996): CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc. Natl. Acad. Sci. USA, 93, 2879-2883.
49. Sato, Y., Roman, M., Tighe, H., Lee, D., Corr, M., Nguyen, Minh-Duc., Silverman, G.J., Lotz, M., Carson, D. A. and Raz, E. (1996): Immunostimulatory DNA sequences necessary for effective intradermal gene immunonization. Science, 273, 352-354.
50. Roman, M., Orozco, E. M., Goodman, J. S., Nguyen, M. D., Sato, Y., Ronaghy, A., Kornbluth, R. S., Richman, D., Carson, D. A. and Raz, E. (1997): Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nature Med. 3, 849-854.
51. Tighe, H., Corr, M., Roman, M. and Raz, E. (1998): Gene vaccination: plasmid DNA is more than just a blueprint. Immunology Today, 19, 89-97.
52. Yi, Ae-K., Tuetken, R., Redford, T., Waldschmidt, M., Kirsch, J. and Krieg, A. M. (1998): CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J. Immunol., 160, 4755-4761.
53. Halpern, M. D., Kurlander, R. J. and Pisetsky, D. S. (1996): Bacterial DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α. Cell. Immunol., 167, 72-78.
54. Yi, A-K., Chace, J. H., Cowdery, J. S. and Krieg, A. M. (1996): IFN-γ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J. Immunol., 157, 558-564.
55. Chace, J. H., Hooker, N. A., Mildenstein, K. L., Krieg, A. M. and Cowdery, J. S. (1997): Bacterial DNA-induces NK cell IFN-γ production is dependent on macrophage secretion of IL-12. Clin. Immunol. Immunopath., 84, 185-193.
56. Anitescu, M., Chace, J. H., Tuetken, B., Yi, Ae-K, Berg, D. J., Krieg, A. M. and Cowdery, J. S. (1997): Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. J. Interferon and Cytokine Res., 17, 781-788.
57. Sweet, M. J., Stacey, K. J., Kakuda, D. K., Markovich, D. and Hume, D. A. (1998): IFN-γ primes macrophage response to bacterial DNA. J. Interferon Cytokine Res., 18, 263-271.
58. Sparwasser, T., Koch, E-S., Vabulas, R. M., Heeg, K., Lipford, G. B., Ellwart, J. W. and Wagner, H. (1998): Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol., 28, 2045-2054.
59. Raz, E., Tighe, H., Sato, Y., Corr, M., Dudler, J.A., Roman, M., Swain, S. L., Spiegelberg, H. L. and Carson, D. A. (1996): Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc. Natl. Acad. Sci. USA, 93, 5141-5145.
60. Benimetskaya, L., Loike, J. D., Khaled, Z., Loike, G., Silverman, S. C., Cao, L., Khoury, J. E., Cai, T-Q. and Stein, C. A. (1997): Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nature Med., 3, 414-420.
61. Yi, A-K., Klinman, D.M., Martin, T. L., Matson, S. and Krieg, A. M. (1996): Rapid immune activation by CpG motifs in bacterial DNA. J. Immunol., 157, 5394-5402.
62. Stacey, K. J., Sweet, M. J. and Hume, D. A. (1996): Macrophages ingest and are activated by bacterial DNA. J. Immunol., 157, 2116-2122.
63. Macfarlane, D. E., Manzel, L. and Krieg, A. M. (1997): Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signalling step. Immunology, 91, 586-593.
64. Yi, A-K., Chang, M., Peckham, D. W., Krieg, A. M. and Ashman, R. F. (1998): CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J. Immunol., 160, 5895-5906.
65. Yi, A-K. and Krieg, A. M. (1998): CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I κ B α and I κ B β and sustained activation of nuclear factor-κ, B/cRel. J. Immunol., 160, 1240-1245.
66. Gregoriadis, G. (1998): Genetic vaccines: Strategies for optimization. Pharmac. Res., 15, 661-670.
67. Klinman, D. M., Yamshchikov, G. and Ishigatsubo, Y. (1997): Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol., 158, 3635-3639.
68. Dennis, M. K. (1998): Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisese Nucleic Acid Drug Develop., 8, 181-184.
69. Lipford, G. B., Beaure, M., Blank, C., Reiter, R., Wagner, H. and Heeg, K. (1997): CpG-containing systhetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol., 27, 2340-2344.
70. Chu, R. A., Targori, O., Krieg, A. M., Lehmann, P. V. and Harding, C. V. (1997): CpG oligodeoxynucleotide act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med., 186, 1623-1631.
71. Carson, D. A. and Raz, E. (1997): Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J. Exp. Med., 186, 1621-1622.
72. Krieg, A. M., Yi, Ae-K., Schorr, J. and Davis, H. L. (1998): The role of CpG dinucleotides in DNA vaccines. Trends Microbiol., 6, 23-27.
73. Leclerc, C., Deriaud, E., Rojas, M. and Whalen, R. G. (1997): The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell. Immunol., 179, 97-106.
74. Weiner, G. J., Liu, H. M., Wooldrodge, E. J., Dahle, C. E. and Krieg, A. M. (1997): Immunostimulatory oligonucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA, 94, 10833-10837.
75. Klinman, D. M. (1998): Therapeutic applications of CpG-containing oligodeoxynucleotides, Antisense Nucleic Acid Drug Develop., 8, 181-184.
76. Moldoveanu, Z., Love-Homan, L., Huang, W. Q. and Krieg, A. M. (1998): CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine, 16, 1216-1224.
77. Lipford, G. B., Sparwasser, T., Bauer, M., Zimmermann, S., Koch, E. S., Heeg, K. K. and Wagner, H. (1997): Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol., 27, 3420-3426.
78. Kataoka, T., Yamamoto, S., Yamamoto, T. and Tokunaga, T. (1990): Immunotherapeutic potential in guinea-pig tumor model of DNA from BCG complexed with poly-L-lysine and carboxymethylcellulose. Jpn. J. Med. Sci. Biol., 43, 171-182.
79. Kline, J. N., Waldschmidt, T. J., Businga, T. R., Lemish, J. E., Weinstock, J. V., Thorne, P. S. and Krieg, A. M. (1998): Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol., 160, 2555-2559.
80. Zimmermann, S., Egeter, O., Hausmann, S., Lipford, G. B., Rocken, M., Wagner, H. and Heeg, K. (1998): Cutting edge: CpG oligodeoxynucleotides tregger protective and curative Th1 response in lethal murine leishmaniasis. J. Immunol., 160, 3627-3630.
81. Wooldridge, J. E., Ballas, Z., Krieg, A. M. and Weiner, G. J. (1997): Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood, 89, 2994-2998.
82. Krieg, A. M. (1996): Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol., 4, 73-77.
83. Pisetsky, D. S. (1997): Immunostimulatory DNA: A clear and present danger ?. Nature Med., 3, 829-831.
84. Schwartz, D. A., Quinn, T. J., Thorne, P. S., Sayeed, S., Yi, A-K. and Krieg, A. M. (1997): CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J. Clin. Invest., 100, 68-73.
85. Cowdery, J. S., Chace, J. H., Yi, A-K. and Krieg, A. M. (1996): Bacterial DNA induces NK Cells to produce IFN-γ in vivo and increases the Toxicity of lipopolysaccharides. J. Immunol., 156, 4570-4575.
86. Sparwasser, T., Miethke, T., Lipford, G., Erdmann, A., Hacker, H., Heeg, K. and Wagner, H. (1997): Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-α -mediated shock. Eur. J. Immunol., 27, 1671-1679.
87. Sparwasser, T., Miethke, T., Lipford, G., Borschert, K., Hacker, H., Heeg, K. and Wagner, H. (1997): Bacterial DNA causes septic shock. Nature, 386, 336-337.
88. Krieg, A. M. (1995): CpG DNA: A pathogenic factor in systemic lupus erythematosus ?. J. Clin. Immunol., 15, 284-292.
89. Miyata, M., Kanno, T., Ishida, T., Kobayashi, H., Sato, Y., Sato, Y., Nishimaki, T. and Kasukawa, R. (1996): CpG motif in DNA from immune complexes of SLE patients augments expression of intercellular adhesion molecule-1 on endothelial cells. Clin. Pathol., (in Japanese), 44, 1125-1131.
90. Segal, B. M., Klinman, D. M. and Shevach, E. M. (1997): Microbial products induce autoimmune disease by an IL-12-dependent pathway. J. Immunol., 158, 5087-5090.
91. Wloch, M. K., Alexander, A. L., Pippen, A. M. M., Pisetsky, D. S. and Gilkeson, G. S. (1997): Molecular properties of anti-DNA induced in preautoimmune NZB/W mice by immunization with bacterial DNA. J. Immunol., 158, 4500-4506.